Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo.
作者信息
Volokhina Elena B, Bergseth Grethe, van de Kar Nicole C A J, van den Heuvel Lambertus P, Mollnes Tom Eirik
机构信息
Department of Pediatric Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands.
Research Laboratory, Nordland Hospital, Bodø, Norway.
出版信息
Blood. 2015 Jul 9;126(2):278-9. doi: 10.1182/blood-2015-03-637645.
Abstract
摘要
相似文献
1
Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo.
Blood. 2015 Jul 9;126(2):278-9. doi: 10.1182/blood-2015-03-637645.
2
Eculizumab fails to inhibit generation of C5a in vivo.
Blood. 2014 Nov 27;124(23):3502-3. doi: 10.1182/blood-2014-07-589366.
3
Response: Maternal and cord C5a in response to eculizumab.
Blood. 2015 Jul 9;126(2):279-80. doi: 10.1182/blood-2015-06-642553.
4
Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses.
Mol Immunol. 2017 Sep;89:111-114. doi: 10.1016/j.molimm.2017.05.021. Epub 2017 Jun 10.
5
Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition.
Clin Immunol. 2017 Jul;180:25-32. doi: 10.1016/j.clim.2017.03.012. Epub 2017 Mar 30.
6
Eculizumab for the treatment of preeclampsia/HELLP syndrome.
Placenta. 2013 Feb;34(2):201-3. doi: 10.1016/j.placenta.2012.11.014. Epub 2012 Dec 8.
7
Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab.
Clin Immunol. 2017 Oct;183:1-7. doi: 10.1016/j.clim.2017.06.007. Epub 2017 Jun 21.
8
9
[C5: eculizumab].
Brain Nerve. 2014 Oct;66(10):1191-9. doi: 10.11477/mf.1416200008.
10
Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway.
J Immunol. 2016 Jul 1;197(1):337-44. doi: 10.4049/jimmunol.1600280. Epub 2016 May 18.
引用本文的文献
1
A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement.
Bone Marrow Transplant. 2023 Sep;58(9):991-999. doi: 10.1038/s41409-023-01996-4. Epub 2023 May 18.
2
The role of C5a-C5aR1 axis in bone pathophysiology: A mini-review.
Front Cell Dev Biol. 2022 Aug 8;10:957800. doi: 10.3389/fcell.2022.957800. eCollection 2022.
3
Modeling the activation of the alternative complement pathway and its effects on hemolysis in health and disease.
PLoS Comput Biol. 2020 Oct 2;16(10):e1008139. doi: 10.1371/journal.pcbi.1008139. eCollection 2020 Oct.
4
Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients.
Proc Natl Acad Sci U S A. 2020 Oct 6;117(40):25018-25025. doi: 10.1073/pnas.2010540117. Epub 2020 Sep 17.
5
Complement System Inhibition Modulates the Pro-Inflammatory Effects of a Snake Venom Metalloproteinase.
Front Immunol. 2019 May 22;10:1137. doi: 10.3389/fimmu.2019.01137. eCollection 2019.
6
Association of age-related macular degeneration with complement activation products, smoking, and single nucleotide polymorphisms in South Carolinians of European and African descent.
Mol Vis. 2019 Feb 8;25:79-92. eCollection 2019.
7
Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults.
Blood. 2017 Aug 17;130(7):891-899. doi: 10.1182/blood-2017-05-781450. Epub 2017 Jun 19.
8
C1q ablation exacerbates amyloid deposition: A study in a transgenic mouse model of ATTRV30M amyloid neuropathy.
PLoS One. 2017 Apr 13;12(4):e0175767. doi: 10.1371/journal.pone.0175767. eCollection 2017.
9
Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
Clin Exp Immunol. 2017 Feb;187(2):304-315. doi: 10.1111/cei.12890. Epub 2016 Nov 25.
10
Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome.
Rheumatology (Oxford). 2016 Jul;55(7):1337-9. doi: 10.1093/rheumatology/kew040. Epub 2016 Apr 22.
本文引用的文献
1
Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn.
Immunobiology. 2015 Apr;220(4):452-9. doi: 10.1016/j.imbio.2014.11.003. Epub 2014 Nov 13.
2
Eculizumab fails to inhibit generation of C5a in vivo.
Blood. 2014 Nov 27;124(23):3502-3. doi: 10.1182/blood-2014-07-589366.
3
An international serum standard for application in assays to detect human complement activation products.
Mol Immunol. 2013 Dec 15;56(3):232-9. doi: 10.1016/j.molimm.2013.05.221. Epub 2013 Jun 17.
4
Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway.
Blood. 2012 Aug 23;120(8):1717-25. doi: 10.1182/blood-2012-02-412080. Epub 2012 Jul 16.
5
Generation of C5a in the absence of C3: a new complement activation pathway.
Nat Med. 2006 Jun;12(6):682-7. doi: 10.1038/nm1419. Epub 2006 May 21.
6
Radioimmunoassay for anaphylatoxins: a sensitive method for determining complement activation products in biological fluids.
Anal Biochem. 1984 Jan;136(1):75-88. doi: 10.1016/0003-2697(84)90308-7.
7
Fluid phase generation of terminal complement complex as a novel index of bioincompatibility.
Kidney Int. 1990 Feb;37(2):696-706. doi: 10.1038/ki.1990.36.
8
Activation of the fifth component of human complement, C5, without cleavage, by methionine oxidizing agents.
Mol Immunol. 1992 Feb;29(2):251-6. doi: 10.1016/0161-5890(92)90106-8.
Zotero 插件